Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapanisertib in Advanced Urothelial Carcinoma With TSC1/TSC2 Mutations
NCT03047213Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2017
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sapanisertib in urothelial carcinoma (UC), sponsored by National Cancer Institute. Started Aug 2017; status: active, not recruiting.
02
Drugs
sapanisertib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03047213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03047213.